After months of waiting for an effective vaccine to combat the pandemic, some countries are kicking off mass COVID-19 vaccinations, bringing hope to people in hard-hit regions.
经过数月等待，能有效对抗新冠病毒的疫苗终于来了，一些国家正在启动大规模新冠疫苗接种，这给疫情严重地区的人们带来了希望。

On Dec 8, the United Kingdom started its large-scale COVID-19 vaccination, with the vaccine developed by the United States pharmaceutical company Pfizer and its German development partner BioNTech. On Dec 14, the US also started its COVID-19 vaccine rollout nationwide, as the death toll of the pandemic in the country topped 300,000, Xinhua reported.
12月8日，英国启动了大规模新冠疫苗接种，该疫苗由美国辉瑞制药公司与其德国研发伙伴BioNTech联合研制。据新华社报道，随着美国新冠疫情死亡人数超过30万，美国也于12月14日在全国开始了首批新冠疫苗接种。

China will also start getting some key groups vaccinated over the winter, Zeng Yixin, deputy head of the National Health Commission (NHC) said at a press conference on Dec 19.
12月19日，国家卫生健康委副主任曾益新在新闻发布会上表示，中国也将在冬季期间对部分重点人群开展疫苗接种工作。

People who engaged in the cold-chain industry, or other high-risk groups who work in healthcare, seafood markets and public transportation, will receive the vaccines first.
从事冷链物流行业，或在医疗、海鲜市场、公共交通领域工作的高风险人群，将率先接种疫苗。

The vaccination program will also cover those who plan to work or study in countries and regions with higher risks of exposure to the virus, according to the NHC.
据国家卫健委表示，接种工作也将涵盖计划前往中高风险国家或者地区工作或学习的人员。

This is the first step in China’s COVID-19 vaccination plan. It will help relieve the pressure in preventing and controlling imported COVID-19 cases and also lower the risk of outbreaks.
这是中国新冠疫苗实施计划的第一步，将有助于缓解预防和控制输入性病例的压力，也会降低疫情暴发风险。

Next, with COVID-19 vaccines officially approved to enter the market and the output of vaccines improving steadily, China will put more vaccines into use. Senior citizens, people with underlying diseases and the general public will then receive vaccines.
下一步，随着新冠疫苗正式获批上市，以及疫苗生产供应能力稳步提高，更多疫苗将在中国投入使用。随后，老年人、患有基础疾病的人群,以及普通人群都将接种疫苗。

According to Xinhua, China’s COVID-19 vaccine development has entered the “final sprint”, with five vaccines undergoing phase-3 clinical trials.
新华社报道称，中国的新冠疫苗研发工作已进入“最后冲刺”阶段，5个疫苗进入三期临床试验。

Over 1 million people at high risk of exposure have been given emergency vaccinations since July. Of those cases, no serious adverse effects have been reported so far, said Zheng Zhongwei from the NHC.
7月份以来我国，已对100多万高风险暴露人群进行了新冠疫苗紧急接种工作。在这些人群中，目前没有报告出现严重的不良反应，国家卫生健康委的郑忠伟介绍道。

According to a report published on the Science magazine website, a COVID-19 vaccine developed by China National Pharmaceutical Group proved to have “outstanding efficacy data”. An analysis shows the vaccine to have 100 percent effectiveness in preventing moderate and severe cases of COVID-19 and no serious safety concerns, Xinhua reported.
根据一份发表于《科学》杂志网站上的报告显示，中国医药集团研发的新冠疫苗被证实“有效性极高”。据新华社报道，一份分析显示，该疫苗具有100%预防中度和重度新冠肺炎病例的有效性，且无严重安全隐患。

As for those who are not among the first groups to receive vaccines, officials at the NHC said there’s no need to be anxious. “We advise the public to maintain personal hygiene and protection, including wearing masks, washing hands and practicing social distancing. These measures prove to be effective protection against the virus,” said Cui Gang, a senior official with the commission.
至于非首批接种疫苗的人群，国家卫生健康委官员表示无需焦虑。“我们建议市民保持个人卫生，做好防护，如戴口罩、洗手、保持社交距离等。这些措施经过证实，可有效抵御病毒，”国家卫健委高级官员崔钢表示。

(Translator & Editor: Wang Yue (Intern) AND Wang Xingwei)
https://www.i21st.cn/story/3634.html